Choosing A Cognitive Supplement: Six Checks

A ranking would require testing. Nobody publishing a list of the best cognitive supplements has assayed the capsules, run a trial or compared them under any controlled condition, and a ranking without that is an ordering of affiliate commissions.

A scorecard makes a different claim. It says: here are six properties of a label that can be established by looking at it, each of which tells you something, and here is what a pass and a fail look like on each.

That has three advantages. It works on a product this desk has never heard of. It produces an answer a reader can check rather than one they have to trust. And it can be applied to the thing the person publishing it sells, which is the section at the end of this page.

It has one honest limitation, set out at the bottom: six passes would not mean a product works. Every check here is about whether a claim can be assessed, not about whether the capsule does anything.

Two passes, one partial, three fails. The scoring is this desk's, applied to the product this desk sells, using the same six checks it recommends for anything else.

Three failures out of six on a product this website earns a commission from is an uncomfortable table to publish, and publishing it is the only thing that makes the two passing rows worth reading.

It is also not a verdict on whether anybody should buy it. Check one and check six are the two that describe what a buyer can actually do: assess the formula, and change their mind for six months. Both are unusually strong here, and a great deal of this aisle fails them.

Check two, the amounts. This is the largest of the three and it is one finding rather than five. The pooled arginine trials put the threshold at four grams a day against a 200 mg row. The citrulline dose-ranging study began at two grams against a 100 mg row. The beta alanine position stand describes four to six grams daily against a 40 mg row. Every amino acid row misses in the same direction by a broadly similar factor, which points at a single design decision: breadth across a pathway rather than depth on any part of it.

Check three, the citrulline malate ratio. A smaller failure and an avoidable one. Citrulline malate is sold at ratios from one-to-one to two-to-one, and the ratio decides how much of the printed weight is citrulline rather than malic acid: roughly 72 mg of that row at two-to-one, roughly 57 mg at one-to-one. The label prints the ratio on its arginine AKG row and not on this one, so the information exists in the house style and simply was not applied here. A head-to-head trial asks whether the malate contributes anything at all, which makes the ratio worth knowing.

Check five, who made it. The artwork carries a distributor, a postal address, a telephone number, an email and an origin statement, which is more than a good deal of this category manages. It names no manufacturer, and the two compliance marks on the pack name no organisation either, so neither can be looked up by a reader. A single line of artwork naming a facility would turn a category claim into a checkable one.

Check one is the most valuable pass on this card. Seven rows with seven amounts and no blend total means everything above could be written at all. A proprietary blend would have made checks two, three and four unanswerable, and a reader would have been left with marketing copy and a price. This is rarer in the aisle than it should be.

Check six is the second. 180 days from the date of purchase with opened bottles included is a term that survives a proper trial of the product. It is a purchase policy rather than a statement about the formula, and it is still the difference between testing something and gambling on it.

Check four sits in between and the partial is deliberate. The vascular rows do reach a cognition label by extension from exercise research, which is the weaker side of the verdict. The beta alanine row is the stronger side: the pooled delayed-recall analysis and the ten-week trial in older adults are aimed squarely at the outcome on the front of the bottle. Somebody specified that row knowing where the evidence was, and the amount is where it comes apart rather than the reasoning.

The card is worth more on a bottle this desk has never seen, so here is how it behaves in the wild.

Check one eliminates a large fraction of the aisle immediately. A proprietary blend ends the exercise, and a reader can put that bottle down in ten seconds.

Check two is where nearly everything that survives check one falls over, which is why the category guide prints the trial quantities for the four main families. Once those numbers are in your head this check takes twenty seconds.

Check three catches the labels doing something clever with weight: a botanical with no standardisation, a mineral with no elemental figure, a salt with no ratio.

Checks five and six are about the seller rather than the formula, and they are the two most people skip. They are also the two that decide what happens when something goes wrong, which is the part a scorecard about ingredients would otherwise never reach.

A bottle scoring five or six is not necessarily effective. It is a bottle whose claims can be examined, from a seller who can be reached, with a term long enough to find out.

Four things, and the first is the important one.

Whether anything works. Every check here is about whether a claim can be assessed. A label could pass all six and contain ingredients with no useful effect at any dose, and it would still pass, because passing means legible rather than effective.

What is actually in the capsule. A printed figure is a declaration by a manufacturer. Only a lot-specific assay from a named laboratory establishes contents, and almost nothing in this aisle publishes one.

Whether it suits you. Interactions, existing conditions and current medication are outside what any label reading can settle, and they are the questions a pharmacist answers in ninety seconds.

Whether the price is fair. The card says nothing about money. NCCIH's guidance and the NIH Office of Dietary Supplements are both worth reading alongside it, and neither is selling anything.